- Research Article
- 10.1016/j.vaccine.2026.128344
Protecting infants from respiratory syncytial virus (RSV) in Ireland: Impact of a national nirsevimab immunisation programme, 2024/2025.
- Mar 19, 2026
- Vaccine
- Laura Paris + 11 more +11
Publications from 2021 to 2026
Showing 10 of 81 papers
Protecting infants from respiratory syncytial virus (RSV) in Ireland: Impact of a national nirsevimab immunisation programme, 2024/2025.
Recommendations for estimating and reporting vaccine effectiveness by time since vaccination: a COVID-19 case study.
Estimating COVID-19 vaccine effectiveness (VE) by time since vaccination (TSV) is essential for understanding how protection may change over time and enables meaningful comparisons across studies. This is important for accurate comparisons of VE against different SARS-CoV-2 variants/sublineages, across age groups, during different periods post vaccination campaign, or by vaccine type/brand. We provide recommendations for case-control VE studies on estimating and reporting VE analyses by TSV, with the aim of improving quality of these estimates. Our recommendations cover study design and pre-analysis considerations, descriptive analyses, choice of categories of TSV, categorical and continuous modeling approaches, and best practices for reporting VE by TSV. Using a real-life case-control study, we apply these recommendations and include accompanying statistical scripts in R and Stata. These recommendations will serve as a practical resource for researchers conducting VE analyses by TSV. We encourage ongoing refinement of them through input from other study groups.
Read moreExcess mortality in Europe estimated by EuroMOMO during the COVID-19 pandemic and previous influenza seasons.
Important questions remain regarding differences in geographical and age-specific mortality patterns as the COVID-19 pandemic evolved in consecutive waves, and how COVID-19 mortality compares to seasonal influenza. In a pandemic situation, excess all-cause mortality provides a more complete and robust measure than cause-specific mortality. Data submitted by 26 countries participating in the European Mortality Monitoring (EuroMOMO) network between 2020 and 2023 was analysed to quantify excess all-cause mortality during the COVID-19 pandemic. Excess mortality from this period was compared to previous influenza seasons from 2014 to 2019. Pooled estimates of excess mortality showed four main waves during the COVID-19 pandemic period, most markedly in people aged 65 years and above, with timing and magnitude that varied between countries. Here we show that prior to implementation of control measures and COVID-19 vaccination, excess mortality greatly exceeded typical seasonal influenza mortality, but later during the pandemic was at levels comparable to influenza.
Read more<p>COVID-19 Vaccine Effectiveness Among Older Adults in 2025/26</p>
Corrigendum to: Effects of the 2018 European summer heatwave on the incidence of sporadic bacterial gastroenteritis in a temperate maritime climate region (Republic of Ireland) [One Health, vol. 20, Article Number 101105
COVID-19 vaccine effectiveness against hospitalisation in older adults, VEBIS hospital network, Europe, September 2024--May 2025
We estimated COVID-19 vaccine effectiveness (VE) against PCR-confirmed SARS-CoV-2 hospitalisation in patients ≥60 years with severe acute respiratory infection, using a multicentre, test-negative case-control study across six European countries between September 2024 and May 2025. We included 352 cases (115 vaccinated; 33%) and 9 980 controls (5 024 vaccinated; 50%). VE was 42% (95%CI:15;61) 14–59 days post-vaccination, 32% (95%CI: -1;54) at 60–119 days, and 36% (95%CI: 2;60) at 120–179 days, and no effect thereafter. Among adults aged 60–79 and ≥80 years, we observed moderate VE against COVID-19 hospitalisation for up to 2 and 4 months, respectively.
Read moreTrends in new HIV diagnoses and factors contributing to late diagnosis among migrant populations in EU/EEA countries, 2014 to 2023
We analysed trends in new HIV diagnoses and factors contributing to late diagnosis among migrants in countries in the European Union (EU)/European Economic Area (EEA) from 2014 to 2023. Of the total reported HIV diagnoses, 45.9% were in migrants, with 13.3% born in EU/EEA countries and 86.7% in non-EU/EEA countries. Late diagnosis was observed in 52.4% of migrants, particularly among non-EU/EEA migrants with heterosexual transmission, regardless of sex. Improved HIV prevention and testing strategies are essential for at-risk migrant populations.
Read morePP408 Topic: AS14–Infections: Sepsis and Septic Shock/Antimicrobial Stewardship/Tropical and Parasite Infections/Other: RESPIRATORY SYNCYTIAL VIRUS (RSV) SURVEILLANCE IN IRELAND OVER A DECADE: AN ANALYSIS OF SEASONAL TRENDS PRIOR TO, DURING, AND AFTER THE COVID-19 PANDEMIC.
Aims & Objectives: Respiratory syncytial virus (RSV) is world’s leading cause of viral acute lower respiratory infections (ALRI) in infants, causing significant morbidity and mortality. In temperate climates, RSV shows seasonality with onset in autumn or early winter, posing significant pressure on health services. Severe RSV-associated ALRI often demands admission to paediatric high-dependency units (PHDU) or paediatric intensive care units (PICU). We aimed to analyse national-level RSV surveillance data in Ireland from 2012 to 2014, with special reference to seasonal trends prior to, during and after COVID-19 pandemic. Methods: Health protection surveillance centre (HPSC) collated weekly national-level RSV positivity reports of infants <1 year, and1-4 years from 2012 to 2024 were used for descriptive statistics and regression analysis, aiming to predict timing of peak incidence based on commencement of RSV season. Results: A notable shift in RSV positivity was noted during post-COVID-19 years, with earlier peaks, notably in November and December, compared to pre-COVID19. Moreover, overall reported RSV identifications within the population increased in 2022 and 2023 compared to pre-COVID-19 period. Compared to 2021-22 there was 1.43-fold increase in RSV in 2022-23, and 1.93-fold increase in 2023-24, considered significant as determined by Chi-square test (P < 0.01). Conclusions: A significant increase in the reporting of RSV among infants and young children was observed with earlier winter peaks during post-COVID-19 era. National-level RSV epidemiological analysis signifies relevance of surveillance-based paediatric critical care demand planning, and highlights te need for an early national implementation of RSV preventative strategies, including monoclonal antibodies for newborn infants and/or maternal RSV immunization. Keywords: Respiratory syncytial virus, epidemiology, Ireland, RSV, Surveillance
Read moreThe impact of the COVID-19 pandemic on physical activity among primary school children in Ireland
BackgroundThe containment measures implemented during COVID-19 to curb the virus’s spread disrupted family life globally and profoundly impacted children’s daily behaviours. A decrease in children’s physical activity during COVID-19 is one such health behaviour change that was observed in many European countries. This study aimed to understand the pandemic’s impact on primary school children’s physical activity in Ireland which is important given the epidemic of childhood obesity and chronic diseases in the long term.MethodsAll Childhood Obesity Surveillance Initiative (COSI) participating countries (n = 45) could voluntarily implement the COVID study as part of their COSI Round 6 (R6) data collection or separately. The parents of First and Second-class primary school children (n = 2,784) who consented to participate in COSI-Ireland R6 were invited to complete the family survey which included the standardised COVID study. The COVID module assessed children’s lifestyles and health behaviours before and during the pandemic through 12 questions. Consenting parents supplied their email or postal address and completed the survey in hardcopy or electronically using LimeSurvey. Descriptive statistics were then calculated on the cleaned pseudonymised dataset (n = 1,060) using IBM SPSS Statistics 27.ResultsThe time spent playing actively outside school hours remained the same for some children on both weekdays and weekends (24.2% and 37.1%, respectively). An increase rather than a decrease in the time spent in active play was also observed among almost twice as many children across Ireland on both weekdays (47.3% and 24.2% respectively), and weekends (40.10% and 21.80% respectively).ConclusionsThe positive findings show that the public health messaging from the Irish Government which emphasized the importance of staying active during COVID-19 may have been effective. Further research to assess children’s physical activity during COVID-19 is warranted to inform future pandemics.Key messages• In Ireland, unlike in many European countries, a substantial number of primary school children increased their time spent playing actively during the COVID-19 pandemic.• A unique trend in Irish children’s physical activity levels compared to their European counterparts.
Read moreTrends and geographical variations in outpatient antimicrobial consumption in Ireland in relation to socio-economic deprivation
BackgroundDifferent factors have been associated with changes in antimicrobial consumption rates in Ireland, however the relationship between socio-economic deprivation and antimicrobial consumption has not been explored. The presented ecological analysis explores the temporal and geographical variation in outpatient antimicrobial consumption and socio-economic deprivation in Ireland from January 2015 to March 2022. MethodDeprivation index (DI) was used as a socio-economic proxy. A multilevel mixed model was applied to explore temporal variation and analyse the longitudinal antimicrobial consumption (DID) in relation to DI. Furthermore, maps were generated based on antimicrobial consumption rates, and spatial autocorrelation analyses were carried out to study geographical variation in antimicrobial consumption rates. ResultsThe antimicrobial consumption rates per month varied from 26.2 DID (January 2015) to 22.1 DID (March 2022) showing an overall reduction of 16 %. Overall, total antimicrobial consumption in the multilevel model showed a consistent correlation with higher DI score (6.6 (95%CI 3.9 to 9.3)), and winter season (3.6 (95%CI 3.2 to 3.9)). In contrast, before COVID-19 showed significant lower antimicrobial consumption rates compared to during COVID-19 (−4.0 (95%CI -4.7 to −3.23)). No consistent trends were observed for geographical variation between areas. ConclusionAntimicrobial consumption rates decreased from 2015 to 2021 in Ireland. No geographical patterns were observed in antimicrobial consumption rates but associations between deprivation and antimicrobial consumption rates were observed.
Read more